Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Soludronate
- Development stage
- Phase 3
- Lead developer
- Xeolas Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Soludronate is a topical formulation of alendronic acid, a nitrogen-containing bisphosphonate, developed by Xeolas Pharmaceuticals Limited. It is specifically designed for local application to the alveolar bone following tooth extraction to modulate bone remodeling and prevent alveolar bone loss. By inhibiting farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, alendronic acid disrupts osteoclast activity and induces apoptosis, thereby reducing bone resorption. This topical approach aims to provide localized therapeutic benefits in dental procedures while minimizing systemic exposure associated with oral bisphosphonate therapy.
- Brand names
- Soludronate
- Other names
- alendronic acidalendronate
02
Targets
FDPS (Farnesyl pyrophosphate synthase)
Beyond the preview
Go deeper on Soludronate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Soludronate.